344 related articles for article (PubMed ID: 26740636)
1. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
4. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
[TBL] [Abstract][Full Text] [Related]
5. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
6. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
Toh S; Reichman ME; Graham DJ; Hampp C; Zhang R; Butler MG; Iyer A; Rucker M; Pimentel M; Hamilton J; Lendle S; Fireman BH;
Diabetes Care; 2018 Jan; 41(1):39-48. PubMed ID: 29122893
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
[TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
10. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
[TBL] [Abstract][Full Text] [Related]
12. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
14. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
[TBL] [Abstract][Full Text] [Related]
15. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
16. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
18. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
